Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

BioFocus Signs Agreement with Aviva Investors

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Pre-let agreement for construction of new laboratory and HQ building at Chesterford Research Park.

BioFocus and Aviva Investors have announced the signing of a pre-let agreement for the new Robinson Building, a 60,000 square foot (5,587square metres) facility at Chesterford.

BioFocus will unite the majority of its drug discovery groups within the new complex, affording the company a unique position amongst CROs for support of integrated projects.

Chris Newton of BioFocus explains the decision to move: “BioFocus has been expanding its research activities at Chesterford Park, bringing our expertise in different areas such as structural biology, complex cell assays, and medicinal chemistry closer together. Moving many of these teams into a single, modern and efficient building is an important step forward for the company and will bring added synergies to both our business model and to our scientists.”

Julian Cobourne, Asset Manager for Aviva Investors says: “Chesterford Research Park has provided significant support to BioFocus in meeting its property needs over the years and it has been great to work with them to design a much more efficient laboratory building to meet their future requirements.”

Martin Sylvester of Churchmanor Estates (the joint development partner of Aviva Investors at Chesterford Research Park) commented: “This is great news for Chesterford Research Park and also for the South Cambridge life sciences cluster. Aside from the AstraZeneca deal, this is the largest pre-let in the Cambridge area since 2011 and represents a very significant investment in the region’s economy.”

As the Robinson Building already has outline planning permission, construction is expected to start on site almost immediately.

The building has been designed as two wings, linked by an impressive two-storey atrium and a landscaped courtyard. It has an attractive curved profile which will be enhanced by extensive green landscaping.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Under the terms of the agreement, BioFocus will apply its drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.
Thursday, November 21, 2013
BioFocus Signs Agreement with Biogen Idec
The 3-year collaboration will focus on the identification and validation of novel targets in scleroderma.
Tuesday, November 12, 2013
BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation
Grant will support the development of a novel Parkinson’s disease cell model.
Tuesday, June 25, 2013
BioFocus Launches Academic Engagement Initiative
Aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups.
Wednesday, May 01, 2013
BioFocus Extends its Collaboration with The Michael J. Fox Foundation
BioFocus has extended its collaboration agreement for Parkinson’s Research.
Thursday, April 18, 2013
BioFocus Achieves Milestone in its Drug Discovery Collaboration with UCB
Discovery milestone triggers payment from UCB and demonstrates BioFocus’ ability to support its clients.
Tuesday, December 04, 2012
BioFocus and Ono Sign a Drug Discovery Agreement
The collaboration agreement between Galapagos NV’s service division, BioFocus, and Ono Pharmaceutical Co., Ltd. will focus on discovering novel drugs in the field of CNS disorders.
Monday, September 03, 2012
BioFocus and Activiomics Announces Strategic Alliance
BioFocus expands its drug discovery offering with proteomics technology from Activiomics.
Thursday, July 26, 2012
BioFocus and Argenta Announce Drug Discovery Collaboration
Collaboration with AstraZeneca in respiratory and inflammatory disease.
Thursday, March 15, 2012
Almirall and BioFocus enter Research Alliance
Three-year integrated drug discovery alliance aims to identify drug development candidates for treating respiratory disease.
Wednesday, January 25, 2012
Argenta and BioFocus Announce Two-Year Extension Of Drug Discovery Collaboration with Genentech
Total potential value of the contract extension is up to £21.5 million (€23.4 million).
Monday, August 22, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
The collaboration will offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries.
Wednesday, August 03, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.
Wednesday, July 20, 2011
BioFocus Enters Collaboration with Michael J. Fox Foundation
Collaboration agreement for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.
Thursday, July 14, 2011
BioFocus Extends Collaboration with Usher III Initiative
BioFocus will further advance the project with the objective of delivering a pre-clinical candidate.
Wednesday, June 22, 2011
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos